Nucleic acid drugs antisense oligonucleotides

Diasio, R.B. and Zhang, R. (1997) Pharmacology of therapeutic oligonucleotides. Antisense Nucleic Acid Drug Dev., 7, 239-243. 

Lodmell, J.S., Paillart, J.C., Mignot, D., Ehresmann, B., Ehresmann, C. and Marquet, R. (1998) Oligonucleotide-mediated inhibition of genomic RNA dimerization of HIV-1 strains MAL and LAI A comparative analysis. Antisense Nucleic Acid Drug Dev., 8, 517-529. 

Nakajima, S., Koshino, Y., Nomura, T., Yamashita, F., Agrawal, S., Takakura, Y. and Hashida, M. (2000) Intratumoral pharmacokinetics of oligonucleotides in a tissue-isolated tumor perfusion system. Antisense Nucleic Acid Drug Develop., 10, 105-110. 

Peng, B., Andrews, J., Nestorov, I., Brennan, B., Nicklin, P. and Rowland, M. (2001) Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Develop., 11, 15-27. 

Mann, M.J. (1998) E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts. Antisense Nucleic Acids Drug Dev., 8, 171-176. 

Berdugo, M., et al. 2003. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 13 107. 

Yu, R.Z., J.Q. Su, J.S. Grundy, R.S. Geary, K.L. Sewell, A. Dorr, and A.A. Levin. 2003. Prediction of clinical responses in a simulated phase III trial of Crohn s patients administered the antisense phosphorothio-ate oligonucleotide ISIS 2302 comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. 13 57-66. 

Sommer,W., X. Cui, B. Erdmann, L. Wik-lund, G. Bricca, M. Heilig, and K. Fuxe. 1998. The spread and uptake pattern of in-tracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev. 8 75-85. 

B. Calabretta, G. Zupi, and G. Zon. 1999. Enhanced anti-tumor effects with micro-encapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev. 9 451-458. 

C. York-Defalco, H. Sasmor, B. Conklin, and R.S. Geary. 2000. Absorption of anti-sense oligonucleotides in rat intestine effect of chemistry and length. Antisense Nucleic Acid Drug Dev. 10 35-44. 

P Bridonneau, YF Chang, AV Buvoli, D O Connell, D Parma. Site-directed selection of oligonucleotide antagonists by competitive elution. Antisense Nucleic Acid Drug Dev 9 1-11, 1999. 

Mandiyan S, Schumacher C, Cioffi C, et al, Molecular and cellular characterization of baboon C-Raf as target for antiproliferative effects of antisense oligonucleotides, Antisense Nucleic Acid Drug Dev 1997 7(6) 539-548,... 

Jenison RD, Jennings SD, Walker DW, Bargatze RF, Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion, Antisense Nucleic Acid Drug Dev, 8 265-279, 1998. 

Aynie, I. Vauthier, C. Chacun, H. Fattal, E. Couvreur, P. Spongelike alginate nanopartides as a new potential system for the delivery of antisense oligonucleotides, antisense. Nucleic Acid Drug Dev. 1999, 9, 301-312. 

Miyagishi M, Hayashi M, Taira K (2003). Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13 1-7. 

Agrawal S, Zhao Q (1998). Mixed backbone oligonucleotides Improvement in oligonucleitide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8 135-139. 

Stein CA. How to design an antisense oligonucleotide experiment a consensus approach. Antisense Nucleic Acid Drug Dev 1 998 8 129-132. 

Gelfi, C., et al.. Analysis of antisense oligonucleotides by capillary electrophoresis, gel-slab electrophoresis, and HPLC a comptaison. Antisense Nucleic Acid Drug Dev, 6, 47, 1996. 

Hawley, R et al. Comparison of binding of N3 ->P5 phosphoramidate and phosphorothioate oligonucleotides to cell surface proteins of cultured cells. Antisense Nucleic Acid Drug Dev., 9, 61, 1999. 

Manoharan M (2002) Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev 12 103-128... 

Agrawal S, Tan W, Cai Q et al (1997) In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev 7 245-249... 

---